Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Sage Therapeutics, Inc.

< Previous 1 2 Next >
Sage Therapeutics Announces First Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics to Present at the Stifel 2023 CNS Days
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics Appoints Jessica Federer to Board of Directors
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics Announces European Medicines Agency Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
From Sage Therapeutics, Inc.
Via Business Wire
Tickers BIIB SAGE
Sage Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics to Provide Update on 2023 Key Initiatives at 41st Annual J.P. Morgan Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
From Sage Therapeutics, Inc.
Via Business Wire
Tickers BIIB SAGE
Sage Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics and Biogen to Host Investor Webcast on December 6, 2022 to Discuss Potential Commercialization Plans for Zuranolone
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics to Present at the Stifel 2022 Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics and Biogen Present New Analyses at Psych Congress Further Evaluating the Efficacy and Safety of Zuranolone
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics to Present at Upcoming August Investor Conferences
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics to Present at Upcoming June Investor Conferences
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics to Present at Bank of America Securities 2022 Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics Announces First Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD)
From Sage Therapeutics, Inc.
Via Business Wire
Tickers BIIB SAGE
Sage Therapeutics to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.